Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/128715
Título: Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain
Autores/as: Mestre-Ferrándiz, Jorge
Rivero, Agustín
Orrico-Sánchez, Alejandro
Hidalgo, Álvaro
Abdalla, Fernando
Martín, Isabel
Álvarez, Javier
García-Cenoz, Manuel
del Carmen Pacheco, Maria
Garcés-Sánchez, María
Zozaya González, Mª Neboa 
Ortiz-de-Lejarazu, Raúl
Clasificación UNESCO: 32 Ciencias médicas
320505 Enfermedades infecciosas
Palabras clave: Mcda
Monoclonal Antibodies
Multi-Criteria Decision Analysis
Prevention
Respiratory Syncytial Virus
Fecha de publicación: 2024
Publicación seriada: BMC Infectious Diseases 
Resumen: Background: Respiratory syncytial virus (RSV) is a highly infectious disease that poses a significant clinical and medical burden, as well as social disruption and economic costs, recognized by the World Health Organization as a public health issue. After several failed attempts to find preventive candidates (compounds, products, including vaccines), new alternatives might be available, one being nirsevimab, the first and only option approved for RSV prevention in neonates and infants during their first RSV season. The objective of this study was to develop a novel multi-criteria decision analysis (MCDA) framework for RSV antibody-based preventive alternatives and to use it to assess the value of nirsevimab vs. placebo as a systematic immunization approach to prevent RSV in neonates and infants during their first RSV season in Spain. Methods: Based on a pre-established model called Vaccinex, an ad-hoc MCDA framework was created to reflect relevant attributes for the assessment of current and future antibody-based preventive measures for RSV. The estimated value of nirsevimab was obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 9 experts. A retest and three sensitivity analyses were conducted. Results: Nirsevimab was evaluated through a novel framework with 26 criteria by the committee as a measure that adds value (positive final estimated value: 0.56 ± 0.11) to the current RSV scenario in Spain, by providing a high efficacy for prevention of neonates and infants. In addition, its implementation might generate cost savings in hospitalizations and to the healthcare system and increase the level of public health awareness among the general population, while reducing health inequities. Conclusions: Under a methodology with increasing use in the health field, nirsevimab has been evaluated as a measure which adds value for RSV prevention in neonates and infants during their first RSV season in Spain.
URI: http://hdl.handle.net/10553/128715
DOI: 10.1186/s12879-024-08988-9
Fuente: BMC Infectious Diseases [EISSN 1471-2334], v. 24 (1) p. 1-14, (Enero 2024)
Colección:Artículos
Adobe PDF (3,07 MB)
Vista completa

Visitas

56
actualizado el 07-sep-2024

Descargas

36
actualizado el 07-sep-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.